Press Releases

Press Releases

    Date Title View
    11/09/10
    Summary ToggleHorizon Pharma Presents HZT-501 Long-Term Safety Data and LODOTRA® Phase 3 Data at the American College of Rheumatology Annual Meeting
    11/08/10
    Summary ToggleHorizon Pharma Awarded Therapeutic Discovery Grant
    11/05/10
    Summary ToggleHorizon Pharma, Inc Provides Update on November 4, 2010 FDA Gastrointestinal Drugs Advisory Committee Meeting
    11/02/10
    Summary ToggleHorizon Pharma Announces HZT-501 and LODOTRA® (Modified-Release Prednisone) Data to be Presented at the American College of Rheumatology Annual Meeting
    10/05/10
    Summary ToggleHorizon Pharma Enters into Exclusive Agreement with Mundipharma for Commercialization of LODOTRA® (Modified-Release Prednisone) in Asia
    08/03/10
    Summary ToggleHorizon Pharma, Inc. Files Registration Statement for Proposed Initial Public Offering
    07/23/10
    Summary ToggleHorizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
    06/16/10
    Summary ToggleHorizon Pharma, Inc. Presents Results of Phase 3 Studies of LODOTRA® Demonstrating Statistically Significant Improvement in Response in Rheumatoid Arthritis Patients
    06/09/10
    Summary ToggleHorizon Pharma Announces LODOTRA® and HZT-501 Data to be Presented at the European League Against Rheumatism (EULAR) Annual Congress
    05/26/10
    Summary ToggleHorizon Pharma, Inc. Announces FDA Acceptance of HZT-501 New Drug Application for Filing
    Displaying 1 - 10 of 13 results